The flow cytometry market is expected to register a CAGR of 9.1% to reach USD 4.3 Billion in 2021.
Flow cytometry helps in analysing the expression of cell surface and intracellular molecules. It is used to characterize and define different types of cells in a heterogeneous cell population and facilitates assessing the purity of isolated subpopulations.
Rising global incidence and prevalence of HIV/AIDS and cancer, growing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the fields of immunology and immuno-oncology research, technological advancements, and the increasing incorporation of AI platforms in flow cytometry workflows and advancements in flow cytometry software are some of the factors that have supported long-term expansion for Flow Cytometry Market.
Most end users, such as clinical laboratories, large research facilities, and pharmaceutical companies, require a large number of flow cytometry instruments in order to conduct multiple research studies at the same time. This significantly raises the capital costs associated with the acquisition and maintenance of these devices. Due to limited budgets, such instruments are difficult to obtain for academic and research laboratories. Flow cytometry is widely used in pharmaceutical industry, research as well as clinical laboratories. It acts as a versatile tool with applications in cancer biology, molecular biology, immunology, bacteriology, infectious disease, and virology. Over the last 30 years, it has made dramatic advances, allowing for unprecedented detail in studies of the immune system and other areas of cell biology.
The COVID-19 pandemic has positively impacted this market, as flow cytometry technology is used in several COVID-19 research studies to investigate how the immune system reacts to SARS-CoV-2.
North America dominated the market for flow cytometry and held the largest revenue share of 39.1% in 2020. The region is anticipated to dominate the market throughout the study period. This dominance can be attributed to high healthcare expenditure, well-established healthcare infrastructure, and high adoption of technologically advanced flow cytometry solutions in the U.S.
Insights are provided for each region and major countries within the regions
|
Report Feature |
Descriptions |
|---|---|
|
Market Revenue In 2021 |
USD 4.3 billion |
|
Growth Rate |
CAGR of 9.1% during the forecasting period, 2021-2028 |
|
Historical Data |
2018-2019 |
|
Forecast Years |
2021-2028 |
|
Base Year |
2020 |
|
Units Considered |
Revenue in USD billion and CAGR from 2021 to 2028 |
|
Report Segmentation |
technology, product and service, application, end user and region. |
|
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
|
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and Middle East and Africa |
|
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe) |
|
Companies Profiled |
Danaher Corporation; Becton; Dickinson and Company; Luminex Corporation; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Miltenyi Biotec; Sysmex Corporation; Stratedigm, Inc.; Apogee Flow Systems Ltd.; Sony Biotechnology, Inc.; Thermo Fisher Scientific, Inc. |
|
Available Customization |
In addition to the market data for Flow Cytometry Market, Delvens offers client-centric report and customized according to the company’s specific demand and requirement. |
Flow Cytometry Market is segmented into technology, product and service, application, end user and region.
.png)
.png)
.png)
.png)
.png)
.png)